Highmark Commercial Medical Policy - Pennsylvania |
Medical Policy: | I-150-003 |
Topic: | Daratumumab (Darzalex™) |
Section: | Injections |
Effective Date: | April 30, 2018 |
Issue Date: | April 30, 2018 |
Last Reviewed: | March 2018 |
Daratumumab (Darzalex™) is an immunoglobulin G1 kappa (IgG1k) human monoclonal antibody against CD38 antigen indicated for the treatment of individuals with multiple myeloma. |
This policy is designed to address medical guidelines that are appropriate for the majority of individuals with a particular disease, illness, or condition. Each person's unique clinical circumstances may warrant individual consideration, based on review of applicable medical records.
Policy Position Coverage is subject to the specific terms of the member’s benefit plan. |
Daratumumab (Darzalex) may be considered medically necessary for the treatment of multiple myeloma in individuals who meet ANY of the following criteria:
The use of daratumumab (Darzalex) for all other indications not listed above is considered experimental/investigational, and therefore not covered, as the safety and effectiveness cannot be established by review of the available published peer-reviewed literature.
NOTE: Dosage recommendations per the FDA label.
Place of Service: Outpatient |
Experimental/Investigational (E/I) services are not covered regardless of place of service.
Daratumumab (Darzalex) is typically an outpatient procedure which is only eligible for coverage as an inpatient procedure in special circumstances, including, but not limited to, the presence of a co-morbid condition that would require monitoring in a more controlled environment such as the inpatient setting.
The policy position applies to all commercial lines of business |
Denial Statements |
Services that do not meet the criteria of this policy will be considered experimental/investigational (E/I). A network provider can bill the member for the experimental/investigational service. The provider must give advance written notice informing the member that the service has been deemed E/I. The member must be provided with an estimate of the cost and the member must agree in writing to assume financial responsibility in advance of receiving the service. The signed agreement must be maintained in the provider’s records.
Links |
08/2016, Daratumumab (Darzalex™) – New Coverage Criteria
04/2018, Coverage Guidelines Revised for Dartamumab (Darzalex)